risperidone has been researched along with Panic Attacks in 8 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "On the last-observation-carried forward analysis of repeated measures analysis of variance (ANOVA), risperidone was not more effective than placebo for the CGI-21 Anxiety score or the other anxiety outcome measures." | 9.14 | Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. ( Gonzalez, R; Harnett-Sheehan, K; Janavs, J; Keck, PE; McElroy, SL; Rogers, J; Sheehan, DV; Shivakumar, G; Suppes, T, 2009) |
| "Fifty six subjects with a history of panic attacks were randomized to receive either risperidone or paroxetine." | 9.14 | A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study. ( Cohen, LJ; Galynker, II; Prosser, JM; Steele, A; Yard, S, 2009) |
| "Thirty patients with a primary diagnosis of an anxiety disorder-panic disorder (PD), social anxiety disorder (SAD), or generalized anxiety disorder (GAD)-refractory to initial pharmacotherapy with an adequate (or maximally tolerated) antidepressant and/or benzodiazepine trial of at least 8 weeks' duration prior to study initiation received open-label augmentation with flexibly dosed risperidone for 8 weeks." | 9.12 | An open-label trial of risperidone augmentation for refractory anxiety disorders. ( Christian, KM; Fischmann, D; Hoge, EA; Kinrys, G; Pollack, MH; Simon, NM; Worthington, JJ, 2006) |
| "On the last-observation-carried forward analysis of repeated measures analysis of variance (ANOVA), risperidone was not more effective than placebo for the CGI-21 Anxiety score or the other anxiety outcome measures." | 5.14 | Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. ( Gonzalez, R; Harnett-Sheehan, K; Janavs, J; Keck, PE; McElroy, SL; Rogers, J; Sheehan, DV; Shivakumar, G; Suppes, T, 2009) |
| "Fifty six subjects with a history of panic attacks were randomized to receive either risperidone or paroxetine." | 5.14 | A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study. ( Cohen, LJ; Galynker, II; Prosser, JM; Steele, A; Yard, S, 2009) |
| "Thirty patients with a primary diagnosis of an anxiety disorder-panic disorder (PD), social anxiety disorder (SAD), or generalized anxiety disorder (GAD)-refractory to initial pharmacotherapy with an adequate (or maximally tolerated) antidepressant and/or benzodiazepine trial of at least 8 weeks' duration prior to study initiation received open-label augmentation with flexibly dosed risperidone for 8 weeks." | 5.12 | An open-label trial of risperidone augmentation for refractory anxiety disorders. ( Christian, KM; Fischmann, D; Hoge, EA; Kinrys, G; Pollack, MH; Simon, NM; Worthington, JJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Perna, G | 1 |
| Alessandra, A | 1 |
| Raffaele, B | 1 |
| Elisa, M | 1 |
| Giuseppina, D | 1 |
| Paolo, C | 1 |
| Maria, N | 1 |
| Daniela, C | 1 |
| Sheehan, DV | 2 |
| McElroy, SL | 2 |
| Harnett-Sheehan, K | 1 |
| Keck, PE | 1 |
| Janavs, J | 1 |
| Rogers, J | 1 |
| Gonzalez, R | 1 |
| Shivakumar, G | 1 |
| Suppes, T | 2 |
| Prosser, JM | 1 |
| Yard, S | 1 |
| Steele, A | 1 |
| Cohen, LJ | 1 |
| Galynker, II | 1 |
| Seo, JS | 1 |
| Jamieson, K | 1 |
| Cosgrove, V | 1 |
| Gwizdowski, IS | 1 |
| Yang, H | 1 |
| Rapinesi, C | 1 |
| Serata, D | 1 |
| Del Casale, A | 1 |
| Kotzalidis, GD | 1 |
| Romano, S | 1 |
| Milioni, M | 1 |
| Capezzuto, S | 1 |
| Carbonetti, P | 1 |
| Angeletti, G | 1 |
| Fensore, C | 1 |
| Tatarelli, R | 1 |
| Girardi, P | 1 |
| Simon, NM | 1 |
| Hoge, EA | 1 |
| Fischmann, D | 1 |
| Worthington, JJ | 1 |
| Christian, KM | 1 |
| Kinrys, G | 1 |
| Pollack, MH | 1 |
| Abraham, HD | 1 |
| Mamen, A | 1 |
| Takahashi, H | 1 |
| Higuchi, H | 1 |
| Shimizu, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder[NCT00277654] | Phase 3 | 111 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks[NCT00457106] | 90 participants (Anticipated) | Interventional | 2002-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for risperidone and Panic Attacks
| Article | Year |
|---|---|
Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines.
Topics: Antipsychotic Agents; Bipolar Disorder; Humans; Panic Disorder; Piperazines; Quetiapine Fumarate; Ri | 2016 |
4 trials available for risperidone and Panic Attacks
| Article | Year |
|---|---|
Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anxiety; Anxiety Disorders; Bipolar Disorder; Comorbi | 2009 |
A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; | 2009 |
Characteristics of responders and non-responders to risperidone monotherapy or placebo in co-occurring bipolar disorder and anxiety disorder.
Topics: Adult; Antipsychotic Agents; Anxiety Disorders; Bipolar Disorder; Double-Blind Method; Female; Human | 2013 |
An open-label trial of risperidone augmentation for refractory anxiety disorders.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Benzodiazepi | 2006 |
3 other studies available for risperidone and Panic Attacks
| Article | Year |
|---|---|
Electroconvulsive therapy in a physically restrained man with comorbid major depression, severe agoraphobia with panic disorder, and histrionic personality disorder.
Topics: Adult; Agoraphobia; Antimanic Agents; Antipsychotic Agents; Depressive Disorder, Major; Electroconvu | 2012 |
LSD-like panic from risperidone in post-LSD visual disorder.
Topics: Adult; Antipsychotic Agents; Female; Hallucinations; Humans; Lysergic Acid Diethylamide; Male; Panic | 1996 |
Full remission of panic attacks in a schizophrenic patient after switching from haloperidol to risperidone.
Topics: Adult; Female; Haloperidol; Humans; Panic Disorder; Remission, Spontaneous; Risperidone; Schizophren | 2001 |